Biomedical subjects

P Garzone

Publications and source records attributed to P Garzone.

4 recordsLinked to original sources

PubMed1987

Pressure ulcers.

Pressure sores occur when prolonged pressure or shear is applied to the skin of predisposed patients. Prevention requires identification of patients at risk and institution of thorough surveillance and nursing care. Once pressure ulcers occur, treatment decisions are based on the depth of the ulceration. Management consists of motivating the staff, relieving the pressure, debriding the wound, lowering wound bacterial counts and treating complications.

Anti-Infective Agents, Local↗

PubMed1983

Third-generation and investigational cephalosporins: II. Microbiologic review and clinical summaries.

In vitro susceptibility of Streptococcus pyogenes, Staphylococcus aureus, Staphylococcus epidermidis, Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Serratia marcescens, Hemophilus influenzae, Bacteroides fragilis, and Neisseria gonorrhea to three new second-generation and eight third-generation cephalosporins is tabulated. In general, the newer cephalosporins have an extended spectrum of activity against gram-negative bacteria, including Serratia marcescens, Pseudomonas aeruginosa, and Neisseria gonorrhea. They also tend to be active against anaerobes, including Bacteroides fragilis. However, they generally have less activity against gram-positive bacteria when compared with the first- and second-generation cephalosporins. Clinical summaries are given for each of the cephalosporins, with emphasis on the results of comparative clinical trials. These cephalosporins may prove especially useful in nosocomial infections with resistant organisms, intraabdominal infections, febrile episodes in the granulocytopenic patient, and meningitis.

Bacteria↗

PubMed1981

Steady-state moxalactam kinetics: comparisons with other cephalosporins.

Moxalactam is a new beta-lactam antimicrobial with an extended spectrum. Serum concentrations were determined in 14 patients at steady state using bioassay and high-pressure liquid chromatography methods. Mean peak and trough serum concentrations were 195 and 29.5 micrograms/ml for the 20-gm dose and 214 and 28.8 micrograms/ml for the 3-gm dose. Peak and trough levels exceeded the minimum inhibitory concentration of the infecting bacteria in 100% and 67% of the patients. The 3-gm dose is recommended for infections caused by Pseudomonas aeruginosa and other organisms with higher minimum inhibitory concentrations. Half-lifes ranged from 1.7 to 5.7 hr and reflected the varying renal functions of the patients. A relationship (r = 0.878, p less than 0.001) between creatinine clearance and elimination rate constant was established by bivariant linear regression analysis.

Adult↗

PubMedDate not supplied

Third-generation and investigational cephalosporins: I. Structure-activity relationships and pharmacokinetic review.

The structure-relationships and pharmacokinetic properties of the new second- and third-generation cephalosporins are reviewed. The new second-generation cephalosporins include ceforanide, cefotiam, and cefuroxime. The third-generation cephalosporins include cefmenoxime, cefoperazone, cefotaxime, cefsulodin, ceftazidime, ceftizoxime, ceftriaxone, and moxalactam. These new cephalosporins are semisynthetic analogs with different chemical substitutions on a 7-aminocephalosporanic nucleus. As a result of these chemical modifications, improvements in the antibacterial spectrum as well as pharmacokinetic properties have occurred. In general, the new cephalosporins have longer half-lives, higher and prolonged serum concentrations, and increased cerebrospinal fluid penetration. Selected cephalosporins also have increased biliary tract concentrations. A classification scheme for these new agents, based on generation and susceptibility to Pseudomonas aeruginosa, is presented.

Bacteria↗